Browse by author
Lookup NU author(s): Dr Daniel ErskineORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The α-synuclein seed amplification assay (αSyn-SAA) sensitively detects Lewy pathology, the amyloid state of α-synuclein, in the cerebrospinal fluid (CSF) of patients with Parkinson's disease (PD). The αSyn-SAA harnesses the physics of seeding, whereby a superconcentrated solution of recombinant α-synuclein lowers the thermodynamic threshold (nucleation barrier) for aggregated α-synuclein to act as a nucleation catalyst ("seed") to trigger the precipitation (nucleation) of monomeric α-synuclein into pathology. This laboratory setup increases the signal for identifying a catalyst if one is present in the tissue examined. The result is binary: positive, meaning precipitation occurred, and a catalyst is present, or negative, meaning no precipitation, therefore no catalyst. Since protein precipitation via seeding can only occur at a concentration many-fold higher than the human brain, laboratory-elicited seeding does not mean human brain seeding. We suggest that a positive αSyn-SAA reveals the presence of pathological α-synuclein but not the underlying etiology for the precipitation of monomeric α-synuclein into its pathological form. Thus, a positive αSyn-SAA supports a clinical diagnosis of PD but cannot inform disease pathogenesis, ascertain severity, predict the rate of progression, define biology or biological subtypes, or monitor treatment response.
Author(s): Espay AJ, Lees AJ, Cardoso F, Frucht SJ, Erskine D, Sandoval IM, Bernal-Conde LD, Sturchio A, Imarisio A, Hoffman C, Montemagno KT, Milovanovic D, Halliday GM, Manfredsson FP
Publication type: Review
Publication status: Published
Journal: Parkinsonism and Related Disorders
Year: 2025
Volume: 131
Print publication date: 01/02/2025
Online publication date: 27/12/2024
Acceptance date: 26/12/2024
ISSN (print): 1353-8020
ISSN (electronic): 1873-5126
URL: https://doi.org/10.1016/j.parkreldis.2024.107256
DOI: 10.1016/j.parkreldis.2024.107256
PubMed id: 39794217
